In a multicenter, open‐label, phase I/II trial evaluating nivolumab alone or in combination with ipilimumab in SCLC patients, LSD1 expression emerged as a poor prognostic indicator for individuals treated with either nivolumab or the combination of nivolumab and ipilimumab.89 The gene discussed is KDM1A; the disease is small cell lung carcinoma.